Showing results (1011-1020 of 1,072) with videos related to

Sort By:
Pageof 108
Nature Communications|February 10, 2022
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy targetNourhan Abdelfattah, Parveen Kumar, Caiyi Wang, et al.
Neuro-Oncology|April 29, 2017
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patientsJavier M Figueroa, Johan Skog, Johnny Akers, et al.
The Journal of Organic Chemistry|October 2, 2001
Synthesis of a muscarinic receptor antagonist via a diastereoselective Michael reaction, selective deoxyfluorination and aromatic metal-halogen exchange reactionT Mase, I N Houpis, A Akao, et al.
Neuro-Oncology|March 8, 2026
Oncolytic Adenoviral Infection of Chordoma Achieves Treatment Efficacy Associated with Immunologic Response and Tumor Microenvironmental AlterationXizi Wu, Daniel Ledbetter, Jen-Wei Tsai, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2025
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastasesNora M Lawson, Lingqun Ye, Chae Yun Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative StudiesErik H P van Putten, Anne Kleijn, Victor W van Beusechem, et al.
JCI Insight|July 30, 2020
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restorationMartina Ott, Karl-Heinz Tomaszowski, Anantha Marisetty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaFrederick F Lang, Charles Conrad, Candelaria Gomez-Manzano, et al.
Journal of Proteome Research|November 5, 2014
Use of ENCODE resources to characterize novel proteoforms and missing proteins in the human proteomeCarol L Nilsson, Ekaterina Mostovenko, Cheryl F Lichti, et al.
Pageof 108